Search

1 to 10 of 662
Sort by

Library Entry
Temporal changes within the (bladder) tumor microenvironment that accompany the therapeutic effects of the immunocytokine NHS-IL12

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article in which an immunocytokine, NHS-muIL12, which consists of two molecules of murine IL-12 fused to NHS76, a tumor necrosis-targeting human IgG1, was examined as an immunotherapeutic in an orthotopic MB49 luc ...


Library Entry
CD45RA+CCR7− CD8 T cells lacking co-stimulatory receptors demonstrate enhanced frequency in peripheral blood of NSCLC patients responding to nivolumab

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article demonstrating that high numbers of peripheral CD8 T cells expressing differentiation markers and lacking co-stimulatory receptors at baseline are associated with response to nivolumab in NSCLC patients. Authors: ...


Library Entry
Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a short report on the final planned analysis of OPTiM, a randomized open-label phase III trial of T-vec in patients with unresectable stage IIIB–IVM1c melanoma. Authors: Robert H. I. Andtbacka , Frances Collichio , Kevin J....


Library Entry
Safety and enhanced immunostimulatory activity of the DRD2 antagonist ONC201 in advanced solid tumor patients with weekly oral administration

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article reporting the results of a phase I study that evaluated the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of weekly ONC201. Authors: Mark N. Stein , Jyoti Malhotra , Rohinton S. Tarapore , Usha...


Library Entry
Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a case report describing a patient with myasthenia gravis treated with pembrolizumab demonstrating successful outcomes. Authors: Anne Zaremba , Eleftheria Chorti , Finja Jockenhöfer , Saskia Bolz , Selma Sirin , Martin Glas ,...


Library Entry
Prognostic impact of immune gene expression signature and tumor infiltrating immune cells in localized clear cell renal cell carcinoma

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article investigating the correlation of tumor infiltrating immune cell characteristics with rates of recurrence following surgery in localized ccRCC. Authors: Pooja Ghatalia , Jennifer Gordetsky , Fengshen Kuo , ...


Library Entry
Discovery of a novel natural killer cell line with distinct immunostimulatory and proliferative potential as an alternative platform for cancer immunotherapy

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article establishing a novel NK cell line, NK101, from a patient with extra-nodal natural killer/T-cell lymphoma and examining its phenotypic, genomic and functional characteristics. Authors: Hyun Gul Yang , Moon...


Library Entry
Selectively hampered activation of lymph node-resident dendritic cells precedes profound T cell suppression and metastatic spread in the breast cancer sentinel lymph node

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article seeking to map the immune landscape of BrC SLN Authors: Kim M. van Pul , Ronald J.C.L.M. Vuylsteke , Rieneke van de Ven , Elisabeth A. te Velde , Emiel J. Th. Rutgers , Petrousjka M. van den Tol , Hein B.A...


Library Entry
Neurologic toxicity associated with immune checkpoint inhibitors: a pharmacovigilance study

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a research article concluding that ICIs produce a spectrum of distinct classes of neurologic AEs that can cause significant morbidity and mortality and tend to occur early and with class-specific associations. Authors: Douglas B....


Library Entry
The promise of Immuno-oncology: implications for defining the value of cancer treatment

Published in the Journal for ImmunoTherapy of Cancer (JITC), is a position article and guidelines. This paper defines ways in which treatment with I-O is different from other therapies. It also proposes key aspects and attributes of I-O therapies that should be considered in any assessment of...